-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On August 17, Corning Jereh announced that the National Medical Products Administration (NMPA) of China has approved its supplementary application for the pharmaceutical change of the recombinant humanized anti-HER2 bispecific antibody KN026, and agreed that liquid preparations can be used for subsequent clinical studies
KN026 is an anti-HER2 bispecific antibody independently developed by Corning Jerry, which can simultaneously bind to two non-overlapping epitopes of HER2 and block HER2 signaling
In 2018, KN026 was approved by the NMPA and the US FDA, and is currently conducting multiple phase 1/2 clinical trials for HER2 low-expressing or positive breast cancer, advanced HER2-positive gastric and gastroesophageal junction cancer and other HER2-positive solid tumors And other indications
Phase 1 clinical trial results show that KN026 has good tolerability and safety, and still exhibits significant anti-tumor activity in HER2-positive breast cancer patients who have progressed after multi-line anti-HER2 treatment
Reference materials:
[1] Important progress in HER2 dual-antibody preparations! Corning Jereh KN026 liquid preparation was approved for clinical use.
(The original text has been deleted)
